IVD company Virtue Diagnostics has secured $100 million in series B funding to bring clinical tests to China and emerging markets.
Established in 2019 and based in Singapore, the company is focused on providing products for all disease stages, including very early screening, initial diagnosis, treatment monitoring, and minimal residual disease management.
